Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate
Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The purpose of the study was to compare the materno-fetal transplacental transfer of digoxin, flecainide, and amiod...
Gespeichert in:
Veröffentlicht in: | Therapeutic drug monitoring 2000-10, Vol.22 (5), p.582-588 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 588 |
---|---|
container_issue | 5 |
container_start_page | 582 |
container_title | Therapeutic drug monitoring |
container_volume | 22 |
creator | SCHMOLLING, Jan RENKE, Kirsten RICHTER, Oliver PFEIFFER, Kerstin SCHLEBUSCH, Harald HÖLLER, Tobias |
description | Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The purpose of the study was to compare the materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone, another antiarrhythmic agent used in the treatment of fetal tachyarrhythmia, and to assess the effect of an elevated umbilical venous pressure (UVP) on the transfer rate. Isolated lobules of 16 human placentas were dually perfused after spontaneous delivery or caesarean section. The transplacental transfer (area under the curve in the maternal compartment [maternal AUC], area under the curve in the fetal compartment [fetal AUC], kinetic parameters) of digoxin, flecainide, and amiodarone was calculated after these drugs were added to the maternal circuit. In five experiments, the effect of increased UVP on the transplacental transfer rate was assessed by elevating the UVP by 10 cm H2O. Flecainide efflux out of the maternal compartment was significantly greater than that of digoxin (maternal AUC 57.4% +/- 5.1 %/min vs 73.9% +/- 1.5%/min), whereas the flecainide influx into the fetal circulation was smaller (fetal AUC 9.3% +/- 4.1%/min vs 11.5% +/- 2.0%/min). Only in 50% of the experiments were the smallest amounts of amiodarone detectable in the fetal compartment. An elevation of the UVP reduced the influx of digoxin and flecainide into the fetal compartment (fetal AUC) from 11.5% +/- 2.0%/min to 7.4% +/- 1.9%/min and from 9.3% +/- 4.1% to 4.7% +/- 1.4%/min, respectively. Materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone decreases in this sequence. Fetal cardiac insufficiency accompanied by an elevation of the UVP might reduce the transplacental transfer of these drugs, although no significant difference could be found between the reduction of transfer of digoxin and flecainide. |
doi_str_mv | 10.1097/00007691-200010000-00013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72330553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72330553</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-9b9150bf1601ff2b8a8cfeaab211e5fcaea2389e92173169229f582e4eed1b4f3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRb0A0VL4BeQFYtWAH0maLFF5SpXYwDqaOGMwSpxiJxX8BN-M04bWG4-vzoztQwjl7JqzfHHDwlqkOY9EKPhwioZCHpEp46mMYpmkE3Lq_WdI44yxEzLhnMlYpPGU_N6Z9_bb2DnVNSow1lQ4p2ArCo1pK3CtRdo5sF6jo6Bc6z3tPpCua1BoO9iyQ4Bao-o8bXWIKNa4gQ4r2jelqY2Cmm7Qtr2na4fe9w5pa7d9--Eu8GfkWEPt8XzcZ-Tt4f51-RStXh6fl7erSMmYdVFe5jxhpeYp41qLMoNMaQQoBeeYaAUIQmY55oIvJE9zIXKdZAJjxIqXsZYzcrWbu3btV4--KxrjFdY1WAyPLBZCSpYkMoDZDtz-3KEu1s404H4KzorBf_Hvv9j7L7b-Q-vFeEdfNlgdGkf5AbgcAfBBkA4ilPEHLhGJZEL-AeQzkbE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72330553</pqid></control><display><type>article</type><title>Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate</title><source>Journals@Ovid Ovid Autoload</source><source>MEDLINE</source><creator>SCHMOLLING, Jan ; RENKE, Kirsten ; RICHTER, Oliver ; PFEIFFER, Kerstin ; SCHLEBUSCH, Harald ; HÖLLER, Tobias</creator><creatorcontrib>SCHMOLLING, Jan ; RENKE, Kirsten ; RICHTER, Oliver ; PFEIFFER, Kerstin ; SCHLEBUSCH, Harald ; HÖLLER, Tobias</creatorcontrib><description>Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The purpose of the study was to compare the materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone, another antiarrhythmic agent used in the treatment of fetal tachyarrhythmia, and to assess the effect of an elevated umbilical venous pressure (UVP) on the transfer rate. Isolated lobules of 16 human placentas were dually perfused after spontaneous delivery or caesarean section. The transplacental transfer (area under the curve in the maternal compartment [maternal AUC], area under the curve in the fetal compartment [fetal AUC], kinetic parameters) of digoxin, flecainide, and amiodarone was calculated after these drugs were added to the maternal circuit. In five experiments, the effect of increased UVP on the transplacental transfer rate was assessed by elevating the UVP by 10 cm H2O. Flecainide efflux out of the maternal compartment was significantly greater than that of digoxin (maternal AUC 57.4% +/- 5.1 %/min vs 73.9% +/- 1.5%/min), whereas the flecainide influx into the fetal circulation was smaller (fetal AUC 9.3% +/- 4.1%/min vs 11.5% +/- 2.0%/min). Only in 50% of the experiments were the smallest amounts of amiodarone detectable in the fetal compartment. An elevation of the UVP reduced the influx of digoxin and flecainide into the fetal compartment (fetal AUC) from 11.5% +/- 2.0%/min to 7.4% +/- 1.9%/min and from 9.3% +/- 4.1% to 4.7% +/- 1.4%/min, respectively. Materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone decreases in this sequence. Fetal cardiac insufficiency accompanied by an elevation of the UVP might reduce the transplacental transfer of these drugs, although no significant difference could be found between the reduction of transfer of digoxin and flecainide.</description><identifier>ISSN: 0163-4356</identifier><identifier>DOI: 10.1097/00007691-200010000-00013</identifier><identifier>PMID: 11034264</identifier><identifier>CODEN: TDMODV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Amiodarone - pharmacokinetics ; Amiodarone - therapeutic use ; Anti-Arrhythmia Agents - pharmacokinetics ; Anti-Arrhythmia Agents - therapeutic use ; Antiarythmic agents ; Area Under Curve ; Biological and medical sciences ; Cardiovascular system ; Digoxin - pharmacokinetics ; Digoxin - therapeutic use ; Female ; Fetal Diseases - drug therapy ; Flecainide - pharmacokinetics ; Flecainide - therapeutic use ; Humans ; In Vitro Techniques ; Medical sciences ; Pharmacology. Drug treatments ; Placenta - blood supply ; Placenta - metabolism ; Pregnancy ; Regional Blood Flow ; Tachycardia, Supraventricular - drug therapy ; Umbilical Veins - physiology ; Venous Pressure</subject><ispartof>Therapeutic drug monitoring, 2000-10, Vol.22 (5), p.582-588</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-9b9150bf1601ff2b8a8cfeaab211e5fcaea2389e92173169229f582e4eed1b4f3</citedby><cites>FETCH-LOGICAL-c340t-9b9150bf1601ff2b8a8cfeaab211e5fcaea2389e92173169229f582e4eed1b4f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1525302$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11034264$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SCHMOLLING, Jan</creatorcontrib><creatorcontrib>RENKE, Kirsten</creatorcontrib><creatorcontrib>RICHTER, Oliver</creatorcontrib><creatorcontrib>PFEIFFER, Kerstin</creatorcontrib><creatorcontrib>SCHLEBUSCH, Harald</creatorcontrib><creatorcontrib>HÖLLER, Tobias</creatorcontrib><title>Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate</title><title>Therapeutic drug monitoring</title><addtitle>Ther Drug Monit</addtitle><description>Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The purpose of the study was to compare the materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone, another antiarrhythmic agent used in the treatment of fetal tachyarrhythmia, and to assess the effect of an elevated umbilical venous pressure (UVP) on the transfer rate. Isolated lobules of 16 human placentas were dually perfused after spontaneous delivery or caesarean section. The transplacental transfer (area under the curve in the maternal compartment [maternal AUC], area under the curve in the fetal compartment [fetal AUC], kinetic parameters) of digoxin, flecainide, and amiodarone was calculated after these drugs were added to the maternal circuit. In five experiments, the effect of increased UVP on the transplacental transfer rate was assessed by elevating the UVP by 10 cm H2O. Flecainide efflux out of the maternal compartment was significantly greater than that of digoxin (maternal AUC 57.4% +/- 5.1 %/min vs 73.9% +/- 1.5%/min), whereas the flecainide influx into the fetal circulation was smaller (fetal AUC 9.3% +/- 4.1%/min vs 11.5% +/- 2.0%/min). Only in 50% of the experiments were the smallest amounts of amiodarone detectable in the fetal compartment. An elevation of the UVP reduced the influx of digoxin and flecainide into the fetal compartment (fetal AUC) from 11.5% +/- 2.0%/min to 7.4% +/- 1.9%/min and from 9.3% +/- 4.1% to 4.7% +/- 1.4%/min, respectively. Materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone decreases in this sequence. Fetal cardiac insufficiency accompanied by an elevation of the UVP might reduce the transplacental transfer of these drugs, although no significant difference could be found between the reduction of transfer of digoxin and flecainide.</description><subject>Amiodarone - pharmacokinetics</subject><subject>Amiodarone - therapeutic use</subject><subject>Anti-Arrhythmia Agents - pharmacokinetics</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Antiarythmic agents</subject><subject>Area Under Curve</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Digoxin - pharmacokinetics</subject><subject>Digoxin - therapeutic use</subject><subject>Female</subject><subject>Fetal Diseases - drug therapy</subject><subject>Flecainide - pharmacokinetics</subject><subject>Flecainide - therapeutic use</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Placenta - blood supply</subject><subject>Placenta - metabolism</subject><subject>Pregnancy</subject><subject>Regional Blood Flow</subject><subject>Tachycardia, Supraventricular - drug therapy</subject><subject>Umbilical Veins - physiology</subject><subject>Venous Pressure</subject><issn>0163-4356</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkMtOwzAQRb0A0VL4BeQFYtWAH0maLFF5SpXYwDqaOGMwSpxiJxX8BN-M04bWG4-vzoztQwjl7JqzfHHDwlqkOY9EKPhwioZCHpEp46mMYpmkE3Lq_WdI44yxEzLhnMlYpPGU_N6Z9_bb2DnVNSow1lQ4p2ArCo1pK3CtRdo5sF6jo6Bc6z3tPpCua1BoO9iyQ4Bao-o8bXWIKNa4gQ4r2jelqY2Cmm7Qtr2na4fe9w5pa7d9--Eu8GfkWEPt8XzcZ-Tt4f51-RStXh6fl7erSMmYdVFe5jxhpeYp41qLMoNMaQQoBeeYaAUIQmY55oIvJE9zIXKdZAJjxIqXsZYzcrWbu3btV4--KxrjFdY1WAyPLBZCSpYkMoDZDtz-3KEu1s404H4KzorBf_Hvv9j7L7b-Q-vFeEdfNlgdGkf5AbgcAfBBkA4ilPEHLhGJZEL-AeQzkbE</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>SCHMOLLING, Jan</creator><creator>RENKE, Kirsten</creator><creator>RICHTER, Oliver</creator><creator>PFEIFFER, Kerstin</creator><creator>SCHLEBUSCH, Harald</creator><creator>HÖLLER, Tobias</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20001001</creationdate><title>Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate</title><author>SCHMOLLING, Jan ; RENKE, Kirsten ; RICHTER, Oliver ; PFEIFFER, Kerstin ; SCHLEBUSCH, Harald ; HÖLLER, Tobias</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-9b9150bf1601ff2b8a8cfeaab211e5fcaea2389e92173169229f582e4eed1b4f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amiodarone - pharmacokinetics</topic><topic>Amiodarone - therapeutic use</topic><topic>Anti-Arrhythmia Agents - pharmacokinetics</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Antiarythmic agents</topic><topic>Area Under Curve</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Digoxin - pharmacokinetics</topic><topic>Digoxin - therapeutic use</topic><topic>Female</topic><topic>Fetal Diseases - drug therapy</topic><topic>Flecainide - pharmacokinetics</topic><topic>Flecainide - therapeutic use</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Placenta - blood supply</topic><topic>Placenta - metabolism</topic><topic>Pregnancy</topic><topic>Regional Blood Flow</topic><topic>Tachycardia, Supraventricular - drug therapy</topic><topic>Umbilical Veins - physiology</topic><topic>Venous Pressure</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SCHMOLLING, Jan</creatorcontrib><creatorcontrib>RENKE, Kirsten</creatorcontrib><creatorcontrib>RICHTER, Oliver</creatorcontrib><creatorcontrib>PFEIFFER, Kerstin</creatorcontrib><creatorcontrib>SCHLEBUSCH, Harald</creatorcontrib><creatorcontrib>HÖLLER, Tobias</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic drug monitoring</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SCHMOLLING, Jan</au><au>RENKE, Kirsten</au><au>RICHTER, Oliver</au><au>PFEIFFER, Kerstin</au><au>SCHLEBUSCH, Harald</au><au>HÖLLER, Tobias</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate</atitle><jtitle>Therapeutic drug monitoring</jtitle><addtitle>Ther Drug Monit</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>22</volume><issue>5</issue><spage>582</spage><epage>588</epage><pages>582-588</pages><issn>0163-4356</issn><coden>TDMODV</coden><abstract>Clinical observations suggest that flecainide might pass the placenta more easily than digoxin, and that its transfer is less disturbed in case of hydrops fetalis than that of digoxin. The purpose of the study was to compare the materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone, another antiarrhythmic agent used in the treatment of fetal tachyarrhythmia, and to assess the effect of an elevated umbilical venous pressure (UVP) on the transfer rate. Isolated lobules of 16 human placentas were dually perfused after spontaneous delivery or caesarean section. The transplacental transfer (area under the curve in the maternal compartment [maternal AUC], area under the curve in the fetal compartment [fetal AUC], kinetic parameters) of digoxin, flecainide, and amiodarone was calculated after these drugs were added to the maternal circuit. In five experiments, the effect of increased UVP on the transplacental transfer rate was assessed by elevating the UVP by 10 cm H2O. Flecainide efflux out of the maternal compartment was significantly greater than that of digoxin (maternal AUC 57.4% +/- 5.1 %/min vs 73.9% +/- 1.5%/min), whereas the flecainide influx into the fetal circulation was smaller (fetal AUC 9.3% +/- 4.1%/min vs 11.5% +/- 2.0%/min). Only in 50% of the experiments were the smallest amounts of amiodarone detectable in the fetal compartment. An elevation of the UVP reduced the influx of digoxin and flecainide into the fetal compartment (fetal AUC) from 11.5% +/- 2.0%/min to 7.4% +/- 1.9%/min and from 9.3% +/- 4.1% to 4.7% +/- 1.4%/min, respectively. Materno-fetal transplacental transfer of digoxin, flecainide, and amiodarone decreases in this sequence. Fetal cardiac insufficiency accompanied by an elevation of the UVP might reduce the transplacental transfer of these drugs, although no significant difference could be found between the reduction of transfer of digoxin and flecainide.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11034264</pmid><doi>10.1097/00007691-200010000-00013</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0163-4356 |
ispartof | Therapeutic drug monitoring, 2000-10, Vol.22 (5), p.582-588 |
issn | 0163-4356 |
language | eng |
recordid | cdi_proquest_miscellaneous_72330553 |
source | Journals@Ovid Ovid Autoload; MEDLINE |
subjects | Amiodarone - pharmacokinetics Amiodarone - therapeutic use Anti-Arrhythmia Agents - pharmacokinetics Anti-Arrhythmia Agents - therapeutic use Antiarythmic agents Area Under Curve Biological and medical sciences Cardiovascular system Digoxin - pharmacokinetics Digoxin - therapeutic use Female Fetal Diseases - drug therapy Flecainide - pharmacokinetics Flecainide - therapeutic use Humans In Vitro Techniques Medical sciences Pharmacology. Drug treatments Placenta - blood supply Placenta - metabolism Pregnancy Regional Blood Flow Tachycardia, Supraventricular - drug therapy Umbilical Veins - physiology Venous Pressure |
title | Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A08%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Digoxin,%20flecainide,%20and%20amiodarone%20transfer%20across%20the%20placenta%20and%20the%20effects%20of%20an%20elevated%20umbilical%20venous%20pressure%20on%20the%20transfer%20rate&rft.jtitle=Therapeutic%20drug%20monitoring&rft.au=SCHMOLLING,%20Jan&rft.date=2000-10-01&rft.volume=22&rft.issue=5&rft.spage=582&rft.epage=588&rft.pages=582-588&rft.issn=0163-4356&rft.coden=TDMODV&rft_id=info:doi/10.1097/00007691-200010000-00013&rft_dat=%3Cproquest_cross%3E72330553%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72330553&rft_id=info:pmid/11034264&rfr_iscdi=true |